fda warns against semaglutide injecting copycat FDA warns consumers not to
Description
BMJ Open 12 , e061474 (2022)
This method works by giving GLP-1 receptors in the gastrointestinal tract time to adapt to increased agonist activity before reaching doses that would otherwise trigger severe nausea or vomiting in GLP-1-naive patients
Approximately 15 hours after dosing, the participant developed nausea and vomiting that lasted for 2 days
Note when they occur relative to your tirzepatide injection day
